Description
CC-38 is an experimental immunotherapy being studied for certain types of cancer, including metastatic colorectal cancer (CRC) and metastatic prostate cancer. It is a type of T-cell therapy, which involves using the patient's own immune cells (T-cells) to fight the cancer. In this trial, researchers are investigating whether expanding and re-administering these T-cells (TILs) can help them persist longer in the body and potentially infiltrate the tumor. This is being studied in patients whose cancers have not responded well to standard treatments. The goal is to see if this approach is feasible and safe, and if it shows any signs of effectiveness in these hard-to-treat cancers. This therapy is currently in early-phase clinical trials.
Mechanism of Action
CC-38 is a type of immunotherapy called Tumor-Infiltrating Lymphocyte (TIL) therapy. The process involves collecting T-cells (a type of immune cell) from the patient's tumor or blood. These T-cells are then grown in large numbers in a laboratory (ex vivo expansion). The expanded TILs are then re-infused back into the patient. The idea is that these boosted T-cells will recognize and attack the cancer cells. The specific mechanism by which CC-38 (the expanded TILs) targets cancer cells is being investigated, but it relies on the immune system's ability to identify and destroy tumor cells.
Side Effects
Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.